Robert F. Kennedy Jr.‘s appointment as U.S. Secretary of Health and Human Services has sparked concerns over funding for the National Institutes of Health. Analysts warn that potential cuts to this funding could lead to increased “uncertainty” in the healthcare sector, potentially impacting healthcare stocks.

What Happened: The NIH grants are “very important” sources of funding for a lot of labs out there, said Kyle Mikson, managing director and senior research analyst in conversation with Michael Graham, senior managing director and head of U.S. equity research internet analyst at Canaccord Genuity.

Talking about RFK Jr.’s appointment Mikson said “He’s got some opposition to vaccines, to infectious disease research.” Highlighting the possible funding cuts along with caps on grants, Mikson added, "Things like that are causing uncertainty, causing, you know, stocks to decline."

While, NIH awarded about $2.5 billion in grants in the first six weeks of 2024, this year, that number has plummeted to $1.4 billion.

See Also: Warren Buffett’s Berkshire Boosts Bets On 5 Japanese Companies: Oracle Of Omaha Says Admiration ‘Has Consistently Grown’

Why It Matters: While there isn't going to be a blanket impact of these caps on all healthcare firms, Mikson explains that companies that are academically focused are more likely to be impacted as compared to the ones with a mixed revenue base.

However, when considering investment opportunities, especially for growth-oriented companies with research-driven businesses, the impact is particularly important, Mikson explained.

Here is a list of healthcare sector-linked exchange-traded funds, that investors could consider while trying to gain exposure to the sector.

Read Next:

• Institutional Investors Load Up On Technology And Financial Stocks In Q4 While Reducing Positions In Healthcare Sector Amid Political Uncertainty

Image Via Shutterstock